Clinical Trial Search

Primary: Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per…

Primary: Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation — 3.8; 0 Percentage of…

Primary: Number of Participants With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-off Value — 275 Participants

Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value — 266 Participants

Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 251 Participants

Primary: Hepatitis A Antibodies Titre — 9.4; 9.0; 394.7; 810.6 IU/L

Primary: Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 — 24.4; 2.4…

Primary: Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B — 25.7; 6 percentage of participants — p== 0.0043

Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05

Primary: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 72 — 90.0; 88.1; 0; 0 percentage of participants — p=< 0.001

Primary: Number of Operationally Tolerant Participants — 33 Participants

Primary: Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment — 2; 0; 0; 0 participants

Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Equal to or Above the Cut Off Value. — 265 Participants

Primary: Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 1000 Copies/mL (Polymerase Chain Reaction [PCR]-Based Assay) and Normal…

Primary: Mean Change From Baseline in Viral Quantitative e Antibody — 0.07; 0.15; 0.02; 0.03 Cut-off index (C.O.I.)

Primary: Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values — 72; 71; 64 participants

Primary: Number of Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentration Equal to or Above (≥) 100 Milli-International Units Per Milliliter (mIU/mL) — 88; 84…

Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants

Primary: Feasibility of IVIG Treatment — 23 Participants

Primary: Percentage of Infants With Hepatitis B Infection at 6 Months of Age — 0; 3 Participants

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: HBV-DNA < 300 Copies/mL in 48 Weeks — 79 participants

Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration as Measured by Enzyme-Linked Immunosorbent Assay (ELISA). — 118.6; 14.8; 142.8; 24.2 mIU/mL

Primary: Change in Interferon-stimulated-gene (ISG) Expression — -2.716; 1.670; -2.20; -1.597 log 2 fold change

Primary: Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver — 5 Participants

Primary: Percentage of Participants With HBV Recurrence Prior to or at Week 72 — 0; 0 percentage of participants

Primary: Percent of Participants With Hepatitis B Surface Antigen (HBsAg) Loss by Week 240 — 4.1; 5.2 Percentage of participants — p=0.72

Primary: Anti-Hepatitis B Surface (Anti-HBs) Antibody Concentrations — 1975.7 mIU/mL

Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440

Primary: Number of Subjects Seropositive for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies — 0; 22; 2; 21 subjects